Madrigal Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    549300CHIMT2EUSNJB60
    ISIN
    US5588681057 (MDGL)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    43 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Read full profile

    Fundamentals

    Net revenue
    €439.74M
    Gross margin
    96.3%
    EBIT
    -€264.26M
    EBIT margin
    -60.1%
    Net income
    -€240.45M
    Net margin
    -54.7%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Sibold William John President and CEO -7.6K $400.18 -$3.05M
    Kelley Shannon T General Counsel -1.3K $367.81 -$479.62K
    BATE KENNETH N/A -10K $365.20 -$3.65M
    FRIEDMAN PAUL A N/A -129K $370.24 -$47.82M
    FRIEDMAN PAUL A N/A -47K $355.31 -$16.63M

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 85K $28.18M -76K Sell

    Earnings Calls

    Latest earnings call: May 7, 2024 (Q1 2024)

    Add to watchlist

    Notifications